Avalon GloboCare (ALBT) Stock Price, News & Analysis

Company Overview

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Key Stats

• Today's Range: $3.49 to $3.71
• 50-Day Range: $2.38 to $4.83
• 52-Week Range: $2.11 to $21.60
• Volume: 50,859 shs
• Average Volume: 66,294 shs
• Market Capitalization: $3.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALBT Stock Analysis - Frequently Asked Questions

How have ALBT shares performed this year?

Avalon GloboCare's stock was trading at $3.26 at the beginning of the year. Since then, ALBT shares have increased by 12.3% and is now trading at $3.66.
View the best growth stocks for 2025 here.

How were Avalon GloboCare's earnings last quarter?

Avalon GloboCare Corp. (NASDAQ:ALBT) released its earnings results on Tuesday, November, 13th. The company reported ($0.45) earnings per share for the quarter. The company had revenue of $0.41 million for the quarter.

When did Avalon GloboCare's stock split?

Shares of Avalon GloboCare reverse split on the morning of Monday, October 28th 2024. The 1-15 reverse split was announced on Thursday, October 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Avalon GloboCare?

Shares of ALBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avalon GloboCare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avalon GloboCare investors own include Sangamo Therapeutics (SGMO), Ford Motor (F), Pfizer (PFE), Plug Power (PLUG), NVIDIA (NVDA), Mullen Automotive (MULN) and Intel (INTC).

Company Calendar

• Last Earnings: 11/13/2018
• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALBT
• Previous Symbol: NASDAQ:AVCO
• CUSIP: N/A
• CIK: 1630212
• Web: www.avalon-globocare.com
• Phone: (732) 780-4400
• Fax: 732-780-5600
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($19.9607)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,710,000.00
• Net Margins: -1,125.59%
• Pretax Margin: -1,125.59%
• Return on Equity: N/A
• Return on Assets: -73.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.11

Sales & Book Value

• Annual Sales: $1.26 million
• Price / Sales: 3.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($17.22) per share
• Price / Book: -0.21

Miscellaneous

• Outstanding Shares: 1,090,000
• Free Float: 686,000
• Market Cap: $3.99 million
• Optionable: Not Optionable
• Beta: 0.19